☆ 4.7 Article

Threshold definitions for significant change on the timed 25-foot walk and nine-hole peg test in primary progressive multiple sclerosis

EUROPEAN JOURNAL OF NEUROLOGY (2023)

Related references

Note: Only part of the references are listed.

Article Clinical Neurology

The nine hole peg test as an outcome measure in progressive MS trials

Marcus W. Koch et al.

Summary: This study used patient-level data from two large randomized controlled trials to investigate the performance of alternative scoring methods for the nine-hole peg test (NHPT) in progressive multiple sclerosis (MS). The results showed that the standard NHPT and dominant hand (DH) or non-dominant hand (NDH) alternatives had minimal change, while the NHPT using either hand (EH) resulted in more worsening events. Non-ambulatory patients with progressive MS had more NHPT worsening, especially when using the EH NHPT. Therefore, NHPT can be used as the primary outcome measure in clinical trials involving non-ambulatory patients, but further research is needed to assess its precision in this population.

MULTIPLE SCLEROSIS AND RELATED DISORDERS (2023)

Add to Collection

Article Clinical Neurology

The timed 25-foot walk in a large cohort of multiple sclerosis patients

Anissa Kalinowski et al.

Summary: The study confirms the association of the T25FW with disability and provides evidence of its predictive validity. Walk times in T25FW increased with age, disability, disease type, and disease duration.

MULTIPLE SCLEROSIS JOURNAL (2022)

Add to Collection

Article Clinical Neurology

A comparison of clinical outcomes in PPMS in the INFORMS original trial data set

Marcus W. Koch et al.

Summary: The study compared clinical outcome measures in patients with primary progressive multiple sclerosis, finding that EDSS and T25FW showed the most worsening events, with only a few patients worsening on NHPT, and PASAT scores slightly increased over time.

MULTIPLE SCLEROSIS JOURNAL (2021)

Add to Collection

Article Clinical Neurology

An enrichment strategy for clinical trials in SPMS

Marcus W. Koch et al.

Summary: This study compared disability worsening between different data sets and found a strong association between baseline T25FW and EDSS with T25FW worsening. Specific baseline T25FW and EDSS cut-off scores can be used to predict T25FW worsening events.

MULTIPLE SCLEROSIS JOURNAL (2021)

Add to Collection

Article Clinical Neurology

Repurposing Domperidone in Secondary Progressive Multiple Sclerosis A Simon 2-Stage Phase 2 Futility Trial

Marcus W. Koch et al.

Summary: In this phase 2 futility trial, treatment with the generic drug domperidone did not show efficacy in reducing disability progression in secondary progressive multiple sclerosis (SPMS). Patients with higher prolactin levels during the study had a significantly lower risk of disability progression, indicating a potential avenue for further investigation.

NEUROLOGY (2021)

Add to Collection

Article Clinical Neurology

Comparison of the EDSS, Timed 25-Foot Walk, and the 9-Hole Peg Test as Clinical Trial Outcomes in Relapsing-Remitting Multiple Sclerosis

Marcus W. Koch et al.

Summary: This study compared the performance of EDSS with T25FW and NHPT in a large RRMS trial, finding that T25FW may be more effective, and that the Kaplan-Meier survival analysis method may exaggerate estimates of disability worsening.

NEUROLOGY (2021)

Add to Collection

Article Clinical Neurology

Reliability of Outcome Measures in Clinical Trials in Secondary Progressive Multiple Sclerosis

Marcus W. Koch et al.

Summary: The study compared the frequency of progression and improvement events in SPMS trials using data from the placebo arms of two large RCTs. The EDSS showed the highest rates of improvement over time, with the smallest difference between progression and improvement rates, followed by the T25FW and 9HPT. The findings suggest random variation and measurement error in all investigated outcome measures, with the T25FW and 9HPT showing less than the more established outcome measure EDSS.

NEUROLOGY (2021)

Add to Collection

Article Clinical Neurology

Repurposing Domperidone in Secondary Progressive Multiple Sclerosis

Marcus W. Koch et al.

Summary: The study did not demonstrate the efficacy of domperidone treatment in reducing disability progression in SPMS patients, but found that patients with higher prolactin levels during the study had a lower risk of disability progression.

NEUROLOGY (2021)

Add to Collection

Article Clinical Neurology

Clinical outcome measures in SPMS trials: An analysis of the IMPACT and ASCEND original trial data sets

Marcus W. Koch et al.

MULTIPLE SCLEROSIS JOURNAL (2020)

Add to Collection

Article Clinical Neurology

Effect of natalizumab on disease progression in secondary progressive multiple sclerosis (ASCEND): a phase 3, randomised, double-blind, placebo-controlled trial with an open-label extension

Raja Kapoor et al.

LANCET NEUROLOGY (2018)

Add to Collection

Review Clinical Neurology

The Nine-Hole Peg Test as a manual dexterity performance measure for multiple sclerosis

Peter Feys et al.

MULTIPLE SCLEROSIS JOURNAL (2017)

Add to Collection

Review Clinical Neurology

Validity of the timed 25-foot walk as an ambulatory performance outcome measure for multiple sclerosis

Robert W. Motl et al.

MULTIPLE SCLEROSIS JOURNAL (2017)

Add to Collection

Review Clinical Neurology

The Nine-Hole Peg Test as a manual dexterity performance measure for multiple sclerosis

Peter Feys et al.

MULTIPLE SCLEROSIS JOURNAL (2017)

Add to Collection

Review Clinical Neurology

Validity of the timed 25-foot walk as an ambulatory performance outcome measure for multiple sclerosis

Robert W. Motl et al.

MULTIPLE SCLEROSIS JOURNAL (2017)

Add to Collection

Article Clinical Neurology

Progression on the Multiple Sclerosis Functional Composite in multiple sclerosis: what is the optimal cut-off for the three components?

L. V. A. E. Bosma et al.

MULTIPLE SCLEROSIS JOURNAL (2010)

Add to Collection

Article Clinical Neurology

Disability as an outcome in MS clinical trials

G. C. Ebers et al.

NEUROLOGY (2008)

Add to Collection

Article Clinical Neurology

Glatiramer acetate in primary progressive multiple sclerosis: Results of a multinational, multicenter, double-blind, placebo-controlled trial

Jerry S. Wolinsky et al.

ANNALS OF NEUROLOGY (2007)

Add to Collection

Article Clinical Neurology

Clinical impact of 20% worsening on Timed 25-foot Walk and 9-hole Peg Test in multiple sclerosis

J. J. Kragt et al.

MULTIPLE SCLEROSIS JOURNAL (2006)

Add to Collection

Article Clinical Neurology

Quantitative functional measures in MS: What is a reliable change?

SR Schwid et al.

NEUROLOGY (2002)

Add to Collection

© Peeref 2019-2024. All rights reserved.